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Abstract
AIM
To assess the prevalence, clinical characteristics and 
independent prognostic impact of atrial fibrillation (AF) 
in chronic heart failure (CHF) patients, and the potential 
protective effect of disease-modifying medications, 
particularly beta-blockers (BB). 
METHODS
We retrospectively reviewed the charts of patients 
referred to our center since January 2004, and collected 
all clinical information available at their first visit. 
We assessed mortality to the end of June 2015. We 
compared patients with and without AF, and assessed 
the association between AF and all-cause mortality by 
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multivariate Cox regression and Kaplan-Meyer analysis, 
particularly accounting for ongoing treatment with BB.
RESULTS 
A total of 903 patients were evaluated (mean age 68 
± 12 years, 73% male). Prevalence of AF was 19%, 
ranging from 10% to 28% in patients ≤ 60 and ≥ 77 
years, respectively. Besides the older age, patients with 
AF had more symptoms (New York Heart Association II-
III 60% vs  44%), lower prevalence of dyslipidemia (23% 
vs  37%), coronary artery disease (28% vs  52%) and 
left bundle branch block (9% vs  16%). On the contrary, 
they more frequently presented with an idiopathic 
etiology (50% vs  24%), a history of valve surgery (13% 
vs  4%) and received overall more devices implantation 
(31% vs  21%). The use of disease-modifying 
medications (i.e. , BB and ACE inhibitors/angiotensin 
receptor blockers) was lower in patients with AF (72% 
vs  80% and 71% vs  79%, respectively), who on the 
contrary were more frequently treated with symptomatic 
and antiarrhythmic drugs including diuretics (87% vs  
69%) and digoxin (51% vs  11%). At a mean follow-up 
of about 5 years, all-cause mortality was significantly 
higher in patients with AF as compared to those in 
sinus rhythm (SR) (45% vs  34%, P  value < 0.05 for 
all previous comparisons). However, in a multivariate 
analysis including the main significant predictors of all-
cause mortality, the univariate relationship between 
AF and death (HR = 1.49, 95%CI: 1.15-1.92) became 
not statistically significant (HR = 0.98, 95%CI: 
0.73-1.32). Nonetheless, patients with AF not receiving 
BB treatment were found to have the worst prognosis, 
followed by patients with SR not receiving BB therapy 
and patients with AF receiving BB therapy, who both 
had similarly worse survival when compared to patients 
with SR receiving BB therapy.
CONCLUSION
AF was highly prevalent and associated with older 
age, worse clinical presentation and underutilization 
of disease-modifying medications such as BB in a 
population of elderly patients with CHF. AF had no 
independent impact on mortality, but the underutilization 
of BB in this group of patients was associated to a 
worse long-term prognosis.
Key words: Atrial fibrillation; Chronic heart failure; Beta-
blockers; Digoxin; Prognosis
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Group Inc. All rights reserved.
Core tip: In this retrospective analysis atrial fibrillation 
(AF) was diagnosed in 1 out of 5 patients with chronic 
heart failure. The arrhythmia was associated with older 
age, worse clinical presentation and underutilization 
of disease-modifying medications, particularly beta-
blockers (BB) and ACE inhibitors/angiotensin receptor 
blockers. At a mean follow-up of about 5 years, 
mortality was significantly higher in patients with AF, and 
patients with AF not receiving BB treatment were found 
to have the worst prognosis. However, in a multivariate 
analysis including main significant predictors of all-cause 
mortality, such as age, gender, blood pressure, coronary 
artery disease, comorbidities and medications, the 
univariate relationship between AF and death became 
not statistically significant.
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INTRODUCTION
Atrial fibrillation (AF) is the most common arrhythmia 
and frequently coexists with chronic heart failure 
(CHF)[1]. It is commonly held that CHF decompensated 
by a transient AF episode has better prognosis than 
CHF with permanent AF[2]. However, the real prognostic 
impact of permanent AF in patients with CHF remains 
poorly understood[3-6] and a matter of current debate[7,8]. 
Conflicting data also exist on medical treatment of CHF 
patients with AF, particularly in the elderly. Indeed, 
although beta-blockers (BB) are a corner-stone therapy 
of CHF, their value when AF coexists has recently 
been questioned[9]. Thus, the aim of this study was 
to investigate the prevalence, clinical characteristics 
and prognostic impact of permanent AF in a cohort of 
unselected CHF patients referred to a single tertiary 
outpatient clinic. In particular, we assessed whether 
a diagnosis of permanent AF was independently 
associated with increased all-cause mortality, and 
whether this association was influenced by medical 
therapy with BB. 
MATERIALS AND METHODS
Study population
The study population was drawn from a tertiary 
CHF outpatient clinic; all patients with a diagnosis of 
CHF, New York Heart Association (NYHA) functional 
class between I and III and a readable rest ECG were 
considered eligible. Data were retrospectively collected 
by reviewing all available complete records of the first 
visit at the clinic between January 1st 2004 and May 
31st 2015. A total of 941 unique patients were originally 
included; 23 patients were subsequently excluded 
because they did not have a readable ECG, and another 
10 patients because the heart rhythm was not clearly 
definable due to pacemaker stimulation. Mortality was 
ascertained by consulting hospital and administrative 
databases and death registers. Follow-up was censored 
at June 30, 2015; survival status was not retrievable 
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in five patients, leaving a final study sample of 903 
patients.
All patients signed an informed consent allowing the 
utilization of their anonymized clinical information for 
medical research purposes, as approved by the local 
Institutional Review Board. 
Variables of interest
Permanent AF (subsequently indicated solely as AF) 
was defined as a documented history of AF that had 
persisted for more than 6 mo and was confirmed by a 
surface ECG at first visit. A diagnosis of coronary artery 
disease (CAD) was ascertained by coronary angiography, 
and patients without any luminal stenosis > 50% 
were considered without CAD. Information regarding 
previous percutaneous and/or surgical revasculari-
zation and previous valve surgery was also routinely 
collected. The remaining patients with other CHF etiology 
(including hypertensive cardiac disease, valve disease, 
tachycardiomyopathy, idiopathic cardiomyopathy) 
were all incorporated in a single group. Implanted 
devices were divided as follows: Mono/bicameral pace-
makers (PM), biventricular pacemakers (CRT-D/CRT-P) 
and implantable-cardioverter defibrillators (ICD). 
Hypertension was defined by a blood pressure ≥ 
140/90 and/or the use of antihypertensive medications. 
Diabetes mellitus was defined by history of diabetes 
mellitus and/or a random plasma glucose ≥ 200 mg/dL 
and/or fasting plasma glucose ≥ 126 mg/dL and/or an 
HbA1c ≥ 7% and/or use of antidiabetic treatments. 
Dyslipidemia was defined by history of high cholesterol 
levels and/or a total cholesterol ≥ 200 mg/dL. Present 
or former smoking was ascertained by medical interview, 
and patients who had smoked > 100 cigarettes/year 
were considered as smoker. Cancer history was defined 
by a previous or current malignancy, regardless of 
disease status at the time of medical interview. A clinical 
diagnosis of chronic obstructive pulmonary disease 
(COPD) was made during the visit based on the presence 
of a history of COPD, and/or signs and/or symptoms 
suggestive of COPD including chronic productive cough, 
chronic wheezing, emphysema or bronchitis.
Lab tests completed within 3 mo from the study 
visit were considered to identify anemia (hemoglobin 
levels < 13.5 g/dL in male and < 12.5 g/dL in female 
patients) and chronic kidney disease (CKD: Estimated 
glomerular filtration rate < 60 mL/min per 1.73 m2 as 
calculated from creatinine using the CKD-EPI formula).
The following variables were collected from a basal 
12-lead standard ECG: Heart rhythm, heart rate, and 
presence of a right or left bundle branch block. Left 
ventricular ejection fraction (LVEF) was derived from 
a transthoracic echocardiogram obtained within 3 mo 
from the first visit, and patients with a LVEF > 45% 
were considered as having a preserved LVEF.
Information regarding ongoing medications was 
ascertained for each patient, and included CHF-modi-
fying drugs (i.e., BB, ACE inhibitors and/or angiotensin 
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receptor antagonists (ACEi/ARB) and aldosterone 
antagonists)], diuretics (both loop diuretics and 
thiazides), other blood pressure lowering drugs (such 
as calcium channel blockers and alpha blockers), 
digoxin, amiodarone, lipid-lowering drugs (i.e., statins) 
antiplatelet drugs (including aspirin, clopidogrel and - 
for very few patients - ticagrelor), and anticoagulants 
(i.e., warfarin and very few patients with direct factor X 
or thrombin inhibitors).
Statistical analysis
Continuous variables were expressed as mean ± 
standard deviation (SD), and categorical variables as 
percentages. Characteristics of patients with AF vs 
sinus rhythm (SR) were compared using student’s t 
test and χ 2 test as appropriate. To define univariate 
predictors of all-cause mortality, we compared chara-
cteristics of dead vs alive patients at the end of follow-
up. Univariate and multivariate predictors of mortality 
were also investigated by Cox regression analysis. 
Variables with a P value < 0.10 in univariate analysis 
were selected based on clinical and statistical criteria 
(i.e., to ease the interpretation of the analysis and to 
avoid multicollinearity) and introduced into a multi-
variate model. A backward elimination of variables 
with a P value > 0.05 was performed to obtain the 
final multivariate reduced model. Kaplan-Meyer curves 
were obtained for all-cause mortality in patients with 
AF vs SR, and also based on the use of BB medications. 
All analyses were performed using SAS for Windows 
(version 9.2; SAS Institute Inc, Cary, NC). The statis-




From January 2004 to May 2015, a total of 903 patients 
were evaluated who satisfied our inclusion criteria 
(mean age 68 ± 12 years, 73% male). Prevalence of 
AF was 19%, ranging from 10% to 28% in patients ≤ 
60 and ≥ 77 years of age, respectively (P < 0.0001). 
Characteristics of study population by the presence of 
AF or SR are summarized in Table 1. Patients with AF 
were significantly more symptomatic in comparison to 
patients with SR (NYHA class II-III 60% vs 44%). CAD 
was less common in patients with AF than in those 
with SR (28% vs 52%), as were previous coronary 
revascularization (21% vs 37%) and dyslipidemia (23% 
vs 37%). By contrast, a non-ischemic etiology was more 
frequent in the AF group (50% vs 24%), as well as a 
history of previous valve surgery (13% vs 4%). Patients 
with AF received overall more devices implantation (31% 
vs 21%). ECG data showed a lower prevalence of left 
bundle branch block (9% vs 16%) and a higher mean 
heart rate (80 ± 19 vs 70 ± 13) in patients with AF. 
Patients with AF were more frequently diagnosed with 
CHF with preserved LVEF (29% vs 21%).
Gigli L et al . Atrial fibrillation in chronic heart failure
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Treatment differences in patients with AF 
When AF was present, there was a significant lower 
percentage of treatment with disease-modifying 
medications, including BB (72% vs 80%) and ACEi/ARB 
(51% vs 66%), as well as a less frequent use of calcium 
channel blockers (6% vs 13%), statins (28% vs 49%), 
amiodarone (6% vs 13%) and antithrombotic treatment 
(19% vs 63%). On the contrary, treatment with 
diuretics (87% vs 69%), aldosterone blockers (46% vs 
37%), digoxin (87% vs 69%) and oral anticoagulants 
(82% vs 16%) was lower in patients with SR (Table 1).
Mortality in the study population
At a mean follow-up of 59 ± 40 mo (range 1 to 137 
mo), all-cause mortality was significantly higher in 
patients with AF as compared to those in SR (45% vs 
34%, Figure 1). Patients with AF were more likely to die 
during the course of our extended follow-up (Figure 2). 
Table 2 shows univariate associations of variables listed 
in Table 1 with all-cause mortality. At univariate analysis, 
patients who died had more frequently a diagnosis 
of AF than those who survived (23% vs 16%), were 
significantly older at baseline (71 ± 10 years vs 66 ± 12 
years), had lower systolic and diastolic blood pressure 
(127 ± 19 mmHg vs 130 ± 19 mmHg, 72 ± 10 mmHg 
vs 76 ± 10 mmHg, respectively) and had more often 
NYHA class II-III (60% vs 40%), idiopathic etiology 
of CHF (32% vs 26%), implantable devices (29% vs 
19%), PM stimulation (14% vs 9%) and a history of 
ventricular tachycardia (7% vs 4%). Moreover, diabetes 
mellitus (32% vs 24%), cancer history (14% vs 8%), 
COPD (18% vs 10%), chronic anemia (11% vs 8%), 
CKD (10% vs 6%), and use of diuretics (82% vs 67%), 
digoxin (26% vs 14%) or aldosterone blockers (45% vs 
35%) was more frequent in the group of patients who 
died at follow-up. On the contrary, variables associated 
with survival were the presence of dyslipidemia (27% 
vs 39%), a preserved LVEF (19% vs 24%), and the 
use of BB (72% vs 82%) and ACEi/ARB (75% vs 79%) 
(Table 2). 
In a multivariate analysis including the main signifi-
cant predictors of all-cause mortality, the univariate 
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Figure 1  All-cause mortality in patients with atrial fibrillation and in 
patients with sinus rhythm. SR: Sinus rhythm; AF: Atrial fibrillation.
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Atrial 
fibrillation
(n  = 173)
Sinus 
rhythm
(n  = 
730)
P  value
  Demographics and physical examination
     Age (yr) 72 ± 11 66 ± 12  < 0.0001
     Age ≥ 65 yr (%) 81 60  < 0.0001
     Male gender (%) 70 73 0.42
     SBP (mmHg) 127 ± 18 130 ± 19 0.10
     DBP (mmHg) 74 ± 10 75 ± 10 0.47
     NYHA II-III (%) 60 44     0.0002
  Aetiology
     CAD (%) 28 52  < 0.0001
     Previous CABG/PCI (%) 21 37  < 0.0001
     Without CAD (%) 22 24 0.58
     Others/idiopathic (%) 50 24  < 0.0001
     Valve surgery (%) 13   4  < 0.0001
  Device
     Any PM (%) 30 19   0.001
     CRT-P/CRT-D (%) 10   7 0.14
     ICD (%) 11 16 0.07
     Any Device (%) 31 21   0.005
     History of VT (%) 2   5 0.06
  Risk factors
     Hypertension (%) 61 60 0.81
     Diabetes mellitus (%) 24 28 0.39
     Dyslipidaemia (%) 23 37     0.0004
     Ever smoke (%) 27 41   0.001
  Comorbidities
     Cancer history (%) 12 10 0.47
     COPD (%) 14 13 0.55
     Anaemia (%)   6 10 0.11
     CKD (eGFR < 60) (%)   7   8 0.57
  ECG
     Heart Rate (bpm) 80 ± 19 70 ± 13  < 0.0001
     PM stimulation (%) 24   8   <0.0001
     Right Bundle Branch Block (%)   7   5 0.65
     Left Bundle Branch Block (%)   9 16 0.01
  Echocardiogram
     Preserved LVEF (> 45%) (%) 29 21   0.022
     LVEF (%) 38 ± 14 35 ± 12 0.05
  Medications
     Beta-blockers (%) 72 80 0.01
     ACEi/ARB (%) 71 79 0.02
     Beta-blockers and ACEi/ARB (%) 51 66     0.0003
     Aldosterone blockers (%) 46 37  0.02
     Diuretics (%) 87 69  < 0.0001
     Calcium channel blockers (%)   6 13  0.01
     Alfa-blockers (%)   6   8  0.55
     Digoxin (%) 51 11  < 0.0001
     Statin (%) 28 49  < 0.0001
     Amiodarone (%)   6 13  0.01
     Antithrombotic treatment (%) 19 63  < 0.0001
     OAT (%) 82 16  < 0.0001
     DAPT (%) 2 16  < 0.0001
     OAT and antithrombotic (%)   8   2     0.0006
     Antithrombotic only (%) 11 61  < 0.0001
Table 1  Characteristics of study population by presence of 
atrial fibrillation or sinus rhythm at baseline
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; NYHA: 
New York Heart Association; CAD: Coronary artery disease; CABG: 
Coronary artery bypass grafting; PCI: Percutaneous coronary intervention; 
PM: Pacemaker; CRT-P/D: Cardiac resynchronization therapy pacing/
defibrillator; ICD: Internal cardioverter defibrillator; VT: Ventricular 
tachycardia; COPD: Chronic obstructive pulmonary disease; CKD: Chronic 
kidney disease; eGFR: Estimated glomerular filtration rate (obtained by 
CKD-EPI formula); LVEF: Left ventricular ejection fraction; ACEi: ACE 
inhibitors; ARB: Angiotensin receptor blockers; OAT: Oral anticoagulant 
treatment; DAPT: Dual anti-platelet therapy.
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receiving BB therapy (Figure 3). During the course of 
follow-up, patients with AF not receiving BB treatment 
had the worst prognosis, followed by patients with SR 
not receiving BB therapy together with patients with 
AF receiving BB therapy, and finally patients with SR 
receiving BB therapy (Figure 4).
DISCUSSION
Overall, our data demonstrates that in ambulatory 
patients with CHF, the presence of permanent AF is 
associated with worse clinical presentation, underuse of 
disease-modifying medications including BB, and possibly 
worse prognosis. After accounting for confounders, we 
found no independent association between AF and all-
cause mortality; nonetheless, we found a significantly 
worse prognosis in AF patients with CHF not receiving 
BB treatment.
Patients with AF in our study population were older 
and had a higher NYHA functional class at presentation, 
1.15-1.92) became not statistically significant (HR = 
0.98, 95%CI: 0.73-1.32, Table 3). In the final reduced 
multivariate model, independent predictors at baseline 
of all-cause mortality were the following: Older age, 
male gender, lower systolic blood pressure, NYHA 
class II-III, presence of CAD at coronary angiography, 
presence of an implanted device, diagnosis of diabetes 
mellitus, COPD or anemia, history of cancer, non-use of 
ACEi/ARB and statins, and use of diuretics and digoxin 
(Table 3).
Mortality differences by BB medications
All-cause mortality was studied also through a 
comparison between patients with SR and patients 
with AF based on the presence or absence of BB 
treatment. Patients with AF not receiving BB treatment 
were found to have the worst prognosis, followed by 
patients with SR not receiving BB therapy and patients 
with AF receiving BB therapy, who both had similarly 

















P  value Log-Rank = 0.002
SR
AF
SR    730             540            417             294            151              53                0
AF    173             121              91               60              26                4                0
0               25               50               75              100             125             150
Follow-up (mo)
Figure 2  Kaplan-Meier curves of overall survival according to the presence of atrial fibrillation or sinus rhythm. SR: Sinus rhythm; AF: Atrial fibrillation.
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SR w/BB                    AF w/BB                  SR w/o BB                AF w/o BB
Figure 3  All-cause mortality in patients with atrial fibrillation as compared to patients with sinus rhythm based on the use of beta-blocker medications. SR: 
Sinus rhythm; AF: Atrial fibrillation; BB: Beta-blocker.
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Figure 4  Kaplan-Meier curves of overall survival according to the presence of atrial fibrillation or sinus rhythm and the use of beta-blocker medications. 
SR: Sinus rhythm; AF: Atrial fibrillation; BB: Beta-blocker.
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Death (n  = 324) Alive (n  = 579) P  value HR (95%CI) P  value
  Atrial fibrillation (%) 23 16 0.0085 1.48 (1.14-1.92)     0.0028
  Demographics and physical examination
     Age (yr) 71 ± 10 66 ± 12  < 0.0001      1.05 (1.04-1.06) < 0.0001
     Male gender (%) 25 29  < 0.0001        2.4 (1.85-3.07) < 0.0001
     SBP (mmHg, 10) 127 ± 19 130 ± 19     0.0238      0.93 (0.88-0.99)     0.0228
     DBP (mmHg, 10) 72 ± 10 76 ± 10  < 0.0001      0.76 (0.67-0.85) < 0.0001
     NYHA II-III (%) 60 40  < 0.0001        1.7 (1.35-2.10) < 0.0001
  Aetiology
     CAD (%) 51 46 0.18
     Previous CABG/PCI (%) 33 35 0.57
     Without CAD (%) 17 27     0.0002    0.53 (0.4-0.71) < 0.0001
     Others/idiopathic 32 26   0.049      1.29 (1.02-1.63)     0.0302
     Valve surgery (%)   5   6 0.57
  Device
     Any PM (%) 28 17      0.0003   1.64 (1.29-2.1) < 0.0001
     CRT-P/CRT-D (%) 8   7 0.32
     ICD (%) 20 13     0.0027 1.45 (1.1-1.9)     0.0074
     Any device (%) 29 19     0.0006     1.57 (1.23-2.00)     0.0002
     History of VT (%)   7   4     0.0258     1.53 (1.01-2.32)     0.0439
  Risk factors
     Hypertension (%) 58 61     0.2619
     Diabetes mellitus (%) 32 24     0.0053      1.72 (1.36-2.17) < 0.0001
     Dyslipidaemia (%) 27 39     0.0003      0.68 (0.53-0.87)    0.0023
     Ever smoke (%) 32 41     0.0055     0.92 (0.72-1.16)    0.4668
  Comorbidities
     Cancer history (%) 14   8     0.0044      1.89 (1.37-2.60) < 0.0001
     COPD (%) 18 10     0.0006    1.84 (1.4-2.40) < 0.0001
     Anaemia (%) 11   8     0.0521      2.22 (1.57-3.13) < 0.0001
     CKD (eGFR < 60) (%) 10   6     0.0551    2.807 (1.85-4.25) < 0.0001
  ECG
     Heart rate (bpm, 10) 72 ± 15 70 ± 15     0.1026      1.06 (0.99-1.14)     0.0805
     PM stimulation (%) 14   9     0.0438      1.56 (1.14-2.14)     0.0057
     Right bundle branch block (%)   7   5     0.0866 1.38 (0.9-2.1)     0.1321
     Left bundle branch block (%) 12 16     0.0761      0.75 (0.53-1.05)     0.0958
  Echocardiogram
     Preserved LVEF (> 45%) (%) 19 24   0.056     0.74 (0.56-0.98)     0.0345
     LVEF (%) 34 ± 12 36 ± 11     0.0015      0.98 (0.97-0.99)     0.0008
  Medications
     Beta-blockers (%) 72 82     0.0003     0.67 (0.53-0.85)     0.0012
     ACEi/ARB (%) 75 79     0.0994     0.69 (0.53-0.88)     0.0032
Table 2  Characteristics of study population by survival or death
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LVEF. CHF patients with AF are usually characterized 
by the presence of multiple comorbidities, and it is still 
unknown whether the adverse outcomes associated 
with AF are related to the arrhythmia itself, or to the 
burden of comorbidities associated with this diagnosis[8].
Contrasting findings have been published regarding 
a potential independent contribution of AF to increased 
mortality in patients with CHF. Some studies found AF 
to be an independent predictor of worse outcomes[13,14] 
whereas others found no independent association after 
accounting for confounders[4-6]. Two meta-analyses 
reported a 30%-40% increased risk of mortality when 
CHF is associated with a diagnosis of AF[7,8], irrespective 
of LVEF. In our study population, the coexistence of 
CHF and permanent AF resulted in a worse outcome, 
in agreement with other data reported in the litera-
ture[10,11]. The presence of AF was also associated with 
an increased use of symptomatic medications, such as 
diuretics and digoxin, and a less frequent use of CHF-
modifying medications, such as BB and ACEi/ARB. 
In addition, CAD was less represented among AF 
patients, whereas the prevalence of valve disease and 
non-cardiovascular comorbidities was greater in this 
group of patients, who interestingly also had a higher 
mean LVEF and more frequently a preserved LVEF 
(here LVEF > 45%). Recent literature emphasizes the 
stronger correlation of AF with CHF with preserved 
LVEF as compared to reduced LVEF[12], though this 
association was rather weak in our population, possibly 
because it mainly included CHF patients with reduced 
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     Beta-blockers and ACEi/ARB (%) 32 68  0.003 0.66 (0.53-0.83)    0.0002
     Aldosterone blockers (%) 45 35     0.0033 1.57 (1.26-1.95) < 0.0001
     Diuretics (%) 82 67 < 0.0001   2.5 (1.87-3.31) < 0.0001
     Calcium channel blockers (%) 14 11     0.1588
     Alfa-blockers (%)   8   7     0.8049
     Digoxin (%) 26 14 < 0.0001   1.6 (1.25-2.05)    0.0002
     Statin (%) 39 48    0.0088   0.8 (0.64-1.00)    0.0513
     Amiodarone (%) 12 12    0.8421
     Antithrombotic treatment (%) 56 54    0.5669
     OAT (%) 31 27    0.2374
     DAPT (%) 10 15    0.0282 0.89 (0.62-1.29)    0.5394
     OAT and antithrombotic (%)   3   4    0.4946
     Antithrombotic only (%) 53 50    0.4149
SBP: Systolic blood pressure; DBP: Diastolic blood pressure; NYHA: New York Heart Association; CAD: Coronary artery disease; CABG: Coronary artery 
bypass grafting; PCI: Percutaneous coronary intervention; PM: Pacemaker; CRT-P/D: Cardiac resynchronization therapy pacing/defibrillator; ICD: Internal 
cardioverter defibrillator; VT: Ventricular tachycardia; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; eGFR: Estimated 
glomerular filtration rate (obtained by CKD-EPI formula); LVEF: Left ventricular ejection fraction; ACEi: ACE inhibitors; ARB: Angiotensin receptor 
blockers; OAT: Oral anticoagulant treatment; DAPT: Dual anti-platelet therapy.
Univariate Multivariate full Multivariate reduced
HR (95%CI) P  value HR (95%CI) P  value HR (95%CI) P  value
  Atrial fibrillation   1.48 (1.14-1.92)    0.0028 0.98 (0.73-1.32)   0.8896
  Age (1 yr)   1.05 (1.04-1.06) < 0.0001 1.04 (1.03-1.05)      < 0.0001 1.04 (1.03-1.05) < 0.0001
  Male gender     2.4 (1.85-3.07) < 0.0001 1.45 (1.11-1.90)   0.0068 1.48 (1.13-1.93)    0.0045
  SBP (10 mmHg)   0.93 (0.88-0.99)    0.0228 0.92 (0.86-0.98)   0.0084 0.91 (0.86-0.97)    0.0057
  NYHA II-III     1.7 (1.35-2.10) < 0.0001   1.3 (1.03-1.65)   0.0265 1.32 (1.05-1.66)    0.0195
  Without CAD  0.53 (0.4-0.71) < 0.0001 0.61 (0.44-0.84)   0.0023 0.58 (0.43-0.80)    0.0008
  Any device   1.57 (1.23-2.00)    0.0002 1.65 (1.19-2.29)   0.0028 1.57 (1.23-2.02)    0.0004
  Dyslipidaemia   0.68 (0.53-0.87)  0.002 0.8 (0.60-1.06)   0.1151
  Diabetes mellitus    1.72 (1.36-2.17) < 0.0001 1.63 (1.27-2.08)   0.0001 1.59 (1.25-2.04)    0.0002
  Cancer history    1.89 (1.37-2.60) < 0.0001 1.82 (1.31-2.54)   0.0004 1.84 (1.33-2.56)    0.0003
  COPD          1.84 (1.4-2.4) < 0.0001 1.33 (0.98-1.80)   0.0707 1.38 (1.02-1.86)    0.0359
  Anaemia   2.22 (1.57-3.13) < 0.0001 1.82 (1.23-2.69)   0.0027 1.95 (1.37-2.79)    0.0002
  CKD (eGFR < 60)   2.81 (1.85-4.25) < 0.0001 1.42 (0.87-2.29)   0.1577
  Preserved LVEF (> 45%)   0.74 (0.56-0.98)  0.034 0.91 (0.68-1.22)   0.5369
  PM stimulation   1.56 (1.14-2.14)  0.006 0.91 (0.59-1.40)   0.6561
  Beta-blockers   0.67 (0.53-0.85)  0.001 0.83 (0.64-1.09)   0.1903
  ACEi/ARB   0.69 (0.53-0.88)  0.003 0.77 (0.59-1.01)   0.0634 0.73 (0.56-0.94)    0.0169
  Aldosterone blockers   1.57 (1.26-1.95) < 0.0001 1.11 (0.86-1.43) 0.429
  Diuretics     2.5 (1.87-3.31) < 0.0001 1.51 (1.09-2.10)   0.0134 1.58 (1.17-2.15)    0.0031
  Digoxin     1.6 (1.25-2.05)    0.0002 1.29 (0.97-1.73)   0.0807 1.31 (1.00-1.72)    0.0482
  Statin     0.8 (0.64-1.00)  0.051   0.8 (0.60-1.05)   0.1108 0.71 (0.55-0.90)    0.0057
Table 3  Univariate and multivariate predictors of all-cause mortality
Any device included any pacemaker or internal-cardioverter defibrillator. SBP: Systolic blood pressure; NYHA: New York Heart Association; CAD: 
Coronary artery disease; COPD: Chronic obstructive pulmonary disease; CKD: Chronic kidney disease; eGFR: Estimated glomerular filtration rate by CKD-
EPI formula; LVEF: Left ventricular ejection fraction; PM: Pacemaker; ACEi: ACE inhibitors; ARB: Angiotensin receptor blocker.
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and an ICD implanted showed a statistically significant 
worse prognosis (Table 2). Treatment of LV dyssychrony 
with CRT device is expected to improve EF and 
symptoms over time, which in turn has a major positive 
impact on outcomes, including survival[15]. This is also 
at least partially reflected by the positive prognostic 
association of the presence of a left bundle branch block 
that we found in our study population (Table 2), which 
is likely indicative of the effect of CRT in patients that 
were implanted with a resynchronizing device after the 
first study visit at our clinic.
In contrast to what would be expected, dyslipidemia 
was associated with a reduction of mortality. In the 
setting of CHF, the presence of low cholesterol levels is 
known to identify patients with more advanced cardiac 
disease (i.e., with sarcopenia and possibly cachexia), 
and low concentrations of low-density lipoproteins have 
been associated with worse prognosis[15]. Patients with 
advanced cardiac disease are also less likely to receive 
lipid-lowering medications such as statins, for which 
the indication in CHF patients without active CAD is 
lacking[15]. Thus, the presence of dyslipidemia and the 
use of statins in our CHF population of advanced age 
probably indicate a healthier patient, which explain 
the associations of both these variables with a better 
prognosis. 
Our analysis has several limitations that should be 
acknowledged. First, this is a retrospective analysis, 
thus our findings can only be interpreted with the 
intrinsic limits of this methodology. Second, cardiac 
rhythm was defined at first study visit, and we cannot 
exclude subsequent rhythm modifications. Third, we 
assessed mortality from all causes and could not obtain 
clear information specifically on cardiovascular and non-
cardiovascular mortality. Because a history of cancer 
was a significant predictor of increased mortality, in 
an attempt to remove deaths due to malignancy, we 
performed sensitivity analysis excluding patients with 
a positive history of cancer. This analysis included 812 
patients, of whom 659 with SR (81%) and 153 with 
AF (19%), and a total of 279 deaths out of the original 
324. In this subsample, final results of independent 
predictors of mortality were substantially unchanged 
(data not shown). Finally, due to the low number of 
patients with preserved LVEF, we could not explore the 
interaction between LVEF and AF on mortality. 
Our retrospective cohort study investigating a real-
world population of elderly ambulatory CHF patients 
confirmed the association of AF with older age and 
worse clinical presentation previously reported in the 
literature. It further highlighted how a diagnosis of AF 
also led to an underutilization of disease-modifying 
medications such as BB and ACEi/ARBs, and to a more 
frequent use of symptomatic and antiarrhythmic drugs, 
particularly diuretics and digoxin, which in turn were 
independently associated with worse prognosis. In 
multivariate analysis, AF had no independent impact on 
all-cause mortality, which nonetheless was found to be 
the highest in AF patients not receiving BB medications. 
as shown by the Kaplan-Meyer survival curve in 
Figure 2. However, after adjusting for other significant 
predictors (including older age, male sex, systolic blood 
pressure, NYHA class II-III, ischemic etiology, pacemaker 
implanted, diabetes mellitus, history of cancer, COPD, 
anemia), AF did not show an independent impact on 
overall mortality (Table 3). This finding is in accordance 
with the abovementioned analyses from the COMET[5] 
and the V-HeFT study[4]. Advanced age and CHF severity 
have been shown to largely explain the association 
between AF and mortality in CHF patients, and this 
was also true in our study population, in which beyond 
age and NYHA functional class, we demonstrated 
a significant and independent contribution of non-
cardiovascular comorbidities to mortality, including 
COPD, anemia and a history of cancer.
Although the use of BB in the setting of CHF has 
recently been disputed[9], we observed the worst 
prognosis in AF patients not receiving BB medications, 
while patients with AF receiving BB presented a 
significant survival benefit similar to those with SR not 
receiving BB but still lower than those with SR receiving 
BB treatment (Figures 3 and 4). It is still uncertain 
whether BB therapy reduces morbidity and mortality 
in patients with AF, but a class IA indication is given 
for these medications in patients with CHF and AF to 
control ventricular rate[15]. Our present results support 
this recommendation and point against the underuse of 
BB medications that is generally observed in CHF with 
AF as compared to those with SR[9]. 
The contribution of treatment with digoxin to the 
worse outcome in patients with CHF and AF is a matter 
of current debate[16]. We observed that digoxin was 
used in half of our patients with AF, and in only 1 out 
of 10 patients with SR. These percentages refer to 
the use of digoxin at first study visit, which happened 
some years ago starting in 2004, and probably do not 
reflect the current use of this medication in our clinical 
practice. Trends in the use of digoxin for AF have been 
steadily decreasing in the recent years, at least in the 
American population[17], and this drug has class IIa/B 
recommendations for rate control treatment of AF in 
most recent European[15] and American[18] HF guidelines. 
This is because of an overall neutral effect of this drug 
on mortality[19], and some observational studies showing 
an independent association with increased mortality[20]. 
Accordingly, its utilization was a strong and independent 
predictor of mortality at multivariate analysis in our 
retrospective analysis (Table 3). 
The presence of implantable devices was associated 
with increased mortality in our final multivariate 
model. This finding appears counterintuitive at first, 
but may have different explanations. In particular, the 
presence of a device may be representative of a sicker 
CHF patient, for which the implantation of a device is 
generally indicated. In addition, when we distinguished 
patients with only pacing devices from patients with 
a resynchronizing device (either CRT-P or CRT-D) and 
patients with an ICD, only patients with a pacing device 
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Further prospective randomized studies are needed 
investigating the independent prognostic impact of BB 
treatment in CHF with AF. 
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